Equity Analyst, LightStream Research

Shifara Samsudeen, ACMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

CyberAgent: Game Business Continues to Disappoint but Internet Ad and ABEMA Performs Steadily

Apple: 1Q FY09/21 Earnings Set New All-Time Records

Hoya 3Q Results: Earnings Beat Consensus and Point to Recovery Ahead

Cloopen Group IPO: Growing Demand for Cloud Communications and IoT in China to Drive Growth

Kuaishou IPO Valuation: Attractive Valuation

Suzhou Basecare Medical IPO: First Mover with the Only NMPA-Approved PGT Product in China

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

Suzhou Basecare Medical / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/suzhou-basecare-medical-corporation-limited" target="_blank" data-smartkarma-citation="entities:31087:1" rel="noopener">Suzhou Basecare Medical (MED CH)</a>  offers an innovative platform of genetic testing solutions for assisted reproduction in China. The company’s core product, PGT-A kit (pre-implantation genetic testing) received the NMPA approval in February 2020 and is the only NMPA-approved PGT product in China.The company plans to issue 66.67m shares at an indicative IPO price range of HK$26.36-27.36 per share, and at the midpoint of the IPO price range of HK$26.86 per share, the company will raise net proceeds of HK$1.7bn (US$217m).In our previous insight on the company’s IPO <a href="https://www.smartkarma.com/insights/suzhou-basecare-medical-ipo-first-mover-with-the-only-nmpa-approved-pgt-product-in-china" target="_blank" data-smartkarma-citation="insights:47447" rel="noopener">Suzhou Basecare Medical IPO: First Mover with the Only NMPA-Approved PGT Product in China</a>  we discussed the company’s product pipeline, their future prospects, key drivers and the company’s financials. In this insight, we examine the company’s valuation.

Suzhou Basecare Medical (MED CH)  offers an innovative platform of genetic testing solutions for assisted reproduction in China. The company’s core product, PGT-A kit (pre-implantation genetic testing) received the NMPA approval in February 2020 and is the only NMPA-approved PGT product in China.The company plans to issue 66.67m shares at an indicative IPO price range of HK$26.36-27.36 per share, and at the midpoint of the IPO price range of HK$26.86 per share, the company will raise net proceeds of HK$1.7bn (US$217m).In our previous insight on the company’s IPO Suzhou Basecare Medical IPO: First Mover with the Only NMPA-Approved PGT Product in China  we discussed the company’s product pipeline, their future prospects, key drivers and the company’s financials. In this insight, we examine the company’s valuation.

Suzhou Basecare Medical IPO Valuation: Attractive Even at the Upper End of the IPO Pricing